

Supplemental Table 1. Metrics used by Brady and colleagues to assess the quality of kidney care among nephrology practices

Quality Domain (Weight)	Description	NQF Identifier	NQF Status
Medication Adherence (15%)	ACEi or ARB prescription claims for at least 80% of covered days	0542e	Endorsement removed
	Beta blocker prescription claims for at least 80% of covered days	0542e*	Endorsement removed
	RAAS prescription claims for at least 80% of covered days	0542e*	Endorsement removed
Medication Safety (37.5%)	Serum potassium and a measure of kidney function assessed at least annually in patients receiving an ACEi or ARB	2371	Endorsement removed
	Serum potassium and a measure of kidney function assessed at least annually in patients receiving a diuretic	2371	Endorsement removed
Processes of Care (47.5%)	Annual assessment of parathyroid hormone level in CKD stages 3-5, including dialysis	0571	Endorsement removed
	Annual assessment of calcium and phosphorus, excluding dialysis	0570, 0574	Endorsement removed
	Annual assessment of hemoglobin, excluding dialysis	‡	
	Annual assessment of a lipid panel or LDL cholesterol, including dialysis	0626	Endorsement removed

*Based on a similar measure. ‡, a monthly hemoglobin assessment metric for dialysis (NQF 0370) is no longer endorsed. Weight refers to the importance assigned to the domain by Brady and colleagues for the assignment of quality. ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; RAAS, renin angiotensin aldosterone system; NQF, National Quality Forum; LDL, low density lipoprotein